Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27866761 | 0.91 | HSD11B1 (0.46) | EPHX2EPHX1CTSKCYP2C9HSD11B1 | |
| SCHEMBL12276428 | 0.89 | EPHX1 (0.46) | EPHX1CTSKCYP2C9HSD11B1GAA | |
| Acetic Acid SCHEMBL25356110 | 0.88 | EPHX1 (0.56) | EPHX2EPHX1CYP2C9HSD11B1ALDH1A1 | |
| SCHEMBL8202964 | 0.88 | EPHX1 (0.43) | EPHX1CTSKCYP2C9HSD11B1GAA | |
| SCHEMBL13208 | 0.88 | EPHX1 (0.58) | EPHX2EPHX1CTSKCYP2C9HSD11B1 | |
| SCHEMBL12539827 | 0.84 | CTSK (0.46) | EPHX1CTSKCYP2C9HSD11B1GAA | |
| SCHEMBL89460 | 0.84 | EPHX2 (0.56) | EPHX2EPHX1CTSKCYP2C9HSD11B1 | |
| SCHEMBL18061088 | 0.84 | CA1 (0.49) | EPHX1CTSKCYP2C9HSD11B1GAA | |
| SCHEMBL4510271 | 0.84 | EPHX1 (0.43) | EPHX2EPHX1CTSKCYP2C9HSD11B1 | |
| SCHEMBL18061103 | 0.83 | HSD11B1 (0.47) | EPHX1CTSKCYP2C9HSD11B1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009956-A1 | NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS | Glaxo Group Limited , a corporation | 2010-01-14 | — | — | US | disclosed |
| US-20100009956-A1 | NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS | Glaxo Group Limited , a corporation | 2010-01-14 | — | — | US | disclosed |
| US-20100009956-A1 | NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS | Glaxo Group Limited , a corporation | 2010-01-14 | — | — | US | disclosed |
| EP-2077841-A1 | NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS | Glaxo Group Limited (GB) | 2009-07-15 | — | — | EP | disclosed |
| EP-2030621-A1 | Novel substituted pyrimidines as cysteine protease inhibitors | GLAXO GROUP LIMITED (GB) | 2009-03-04 | — | — | EP | disclosed |
| EP-1947091-A1 | Pyrimidyl nitrile derivatives as cysteine protease inhibitors | GLAXO GROUP LIMITED (GB) | 2008-07-23 | — | — | EP | disclosed |
| EP-1947091-A1 | Pyrimidyl nitrile derivatives as cysteine protease inhibitors | GLAXO GROUP LIMITED (GB) | 2008-07-23 | — | — | EP | disclosed |
| WO-2008052934-A1 | NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-05-08 | — | — | WO | disclosed |
| EP-1918284-A1 | Hydrazinopyrimidines as cysteine protease inhibitors | GLAXO GROUP (GB) | 2008-05-07 | — | — | EP | disclosed |
| EP-1918284-A1 | Hydrazinopyrimidines as cysteine protease inhibitors | GLAXO GROUP (GB) | 2008-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009956-A1 | NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS | SERPINB1, CTRL, PRSS1 | EPHX2 990/4885EPHX1 578/4885CTSK 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.